Germline Genetic Profiling in Prostate Cancer: Latest Developments and Potential Clinical Applications

References

• Ferlay J , ShinHR, BrayF, FormanD, MathersC, ParkinDM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer127(12), 2893–2917 (2010).
   PubMed Web of Science ®Google Scholar
• Prostate Cancer Incidence Statistics. www.cancerresearchuk.org/cancer-info/cancerstats/types/prostate/incidence/.
   Google Scholar
• Marugame T , KatanodaK. International comparisons of cumulative risk of breast and prostate cancer, from cancer incidence in five continents Vol. VIII. Jpn J. Clin. Oncol.36(6), 399–400 (2006).
   PubMed Web of Science ®Google Scholar
• Lee J , DemissieK, LuSE, RhoadsGG. Cancer incidence among Korean-American immigrants in the United States and native Koreans in South Korea. Cancer Control14(1), 78–85 (2007).
   PubMedGoogle Scholar
• Crawford ED . Epidemiology of prostate cancer. Urology62(6 Suppl. 1), 3–12 (2003).
   PubMed Web of Science ®Google Scholar
• Goh CL , SchumacherFR, EastonDet al. Genetic variants associated with predisposition to prostate cancer and potential clinical implications. J. Intern. Med.271(4), 353–365 (2012).
   PubMed Web of Science ®Google Scholar
• Bratt O . Hereditary prostate cancer: clinical aspects. J. Urol.168(3), 906–913 (2002).
   PubMed Web of Science ®Google Scholar
• Huang SP , HuangLC, TingWCet al. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy. Cancer Epidemiol. Biomarkers Prev.18(11), 3068–3074 (2009).
   PubMed Web of Science ®Google Scholar
• O'Brien JM . Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark, and Finland, by P. Lichtenstein, NV Holm, PK Verkasalo, A. Iliadou, J. Kaprio, M. Koskenvuo, E. Pukkala, A. Skytthe, and K. Hemminki. N. Engl. J. Med. 343, 78–84 (2000). Surv. Ophthalmol.45(2), 167–168 (2000).
   PubMedGoogle Scholar
• Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. www.dietandcancerreport.org/cancer_resource_center/downloads/Second_Expert_Report_full.pdf.
   Google Scholar
• Vance TM , SuJ, FonthamET, KooSI, ChunOK. Dietary antioxidants and prostate cancer: a review. Nutr. Cancer65(6), 793–801 (2013).
   PubMed Web of Science ®Google Scholar
• Lippman SM , KleinEA, GoodmanPJet al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA301(1), 39–51 (2009).
   PubMed Web of Science ®Google Scholar
• Labbe DP , ZadraG, EbotEMet al. Role of diet in prostate cancer: the epigenetic link. Oncogene34(36), 4683–4691 (2015).
   PubMed Web of Science ®Google Scholar
• Chan JM , GannPH, GiovannucciEL. Role of diet in prostate cancer development and progression. J. Clin. Oncol.23(32), 8152–8160 (2005).
   PubMed Web of Science ®Google Scholar
• Trottier G , BostromPJ, LawrentschukN, FleshnerNE. Nutraceuticals and prostate cancer prevention: a current review. Nat. Rev. Urol.7(1), 21–30 (2010).
   PubMed Web of Science ®Google Scholar
• Wilson KM , GiovannucciEL, MucciLA. Lifestyle and dietary factors in the prevention of lethal prostate cancer. Asian J. Androl.14(3), 365–374 (2012).
   PubMed Web of Science ®Google Scholar
• Tio M , AndriciJ, CoxMR, EslickGD. Folate intake and the risk of prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis.17(3), 213–219 (2014).
   PubMed Web of Science ®Google Scholar
• John EM , KooJ, SchwartzGG. Sun exposure and prostate cancer risk: evidence for a protective effect of early-life exposure. Cancer Epidemiol. Biomarkers Prev.16(6), 1283–1286 (2007).
   PubMed Web of Science ®Google Scholar
• Carter BS , BeatyTH, SteinbergGD, ChildsB, WalshPC. Mendelian inheritance of familial prostate cancer. Proc. Natl Acad. Sci. USA89(8), 3367–3371 (1992).
   PubMed Web of Science ®Google Scholar
• Cui J , AntoniouAC, DiteGSet al. After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer. Am. J. Hum. Genet.68(2), 420–431 (2001).
   PubMed Web of Science ®Google Scholar
• Gronberg H , DamberL, DamberJE, IseliusL. Segregation analysis of prostate cancer in Sweden: support for dominant inheritance. Am. J. Epidemiol.146(7), 552–557 (1997).
   PubMed Web of Science ®Google Scholar
• Macinnis RJ , AntoniouAC, EelesRAet al. Prostate cancer segregation analyses using 4390 families from UK and Australian population-based studies. Genet. Epidemiol.34(1), 42–50 (2010).
   PubMed Web of Science ®Google Scholar
• Schaid DJ . Transmission disequilibrium, family controls, and great expectations. Am. J. Hum. Genet.63(4), 935–941 (1998).
   PubMed Web of Science ®Google Scholar
• Xu J , DimitrovL, ChangBLet al. A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am. J. Hum. Genet.77(2), 219–229 (2005).
   PubMed Web of Science ®Google Scholar
• Maier C , HaeuslerJ, HerkommerKet al. Mutation screening and association study of RNASEL as a prostate cancer susceptibility gene. Br. J. Cancer92(6), 1159–1164 (2005).
   PubMed Web of Science ®Google Scholar
• Hope Q , BullockS, EvansCet al. Macrophage scavenger receptor 1 999C>T (R293X) mutation and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev.14(2), 397–402 (2005).
   PubMed Web of Science ®Google Scholar
• Wiklund F , JonssonBA, BrookesAJet al. Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer. Clin. Cancer. Res.10(21), 7150–7156 (2004).
   PubMed Web of Science ®Google Scholar
• Gong G , Oakley-GirvanI, WuAHet al. Segregation analysis of prostate cancer in 1,719 white, African-American and Asian-American families in the United States and Canada. Cancer Causes Control13(5), 471–482 (2002).
   PubMed Web of Science ®Google Scholar
• The International HapMap Project. Nature426(6968), 789–796 (2003).
   PubMed Web of Science ®Google Scholar
• A haplotype map of the human genome. Nature437(7063), 1299–1320 (2005).
   PubMed Web of Science ®Google Scholar
• Chung CC , MagalhaesWC, Gonzalez-BosquetJ, ChanockSJ. Genome-wide association studies in cancer–current and future directions. Carcinogenesis31(1), 111–120 (2010).
   PubMed Web of Science ®Google Scholar
• Eeles RK-JZGM , EastonD. The Identification Of Rare And Common Variants Which Predispose To Prostate Cancer. Springer, 229–48 (2010).
   Google Scholar
• Cybulski C , HuzarskiT, GorskiBet al. A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res.64(8), 2677–2679 (2004).
   PubMed Web of Science ®Google Scholar
• Cybulski C , WokolorczykD, HuzarskiTet al. A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. J. Med. Genet.43(11), 863–866 (2006).
   PubMed Web of Science ®Google Scholar
• Erkko H , XiaB, NikkilaJet al. A recurrent mutation in PALB2 in Finnish cancer families. Nature446(7133), 316–319 (2007).
   PubMed Web of Science ®Google Scholar
• Thompson D , SealS, SchutteMet al. A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers. Cancer Epidemiol. Biomarkers Prev.15(12), 2542–2545 (2006).
   PubMed Web of Science ®Google Scholar
• Tischkowitz M , SabbaghianN, RayAM, LangeEM, FoulkesWD, CooneyKA. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in hereditary prostate cancer. Prostate68(6), 675–678 (2008).
   PubMed Web of Science ®Google Scholar
• Risch NJ . Searching for genetic determinants in the new millennium. Nature405(6788), 847–856 (2000).
   PubMed Web of Science ®Google Scholar
• Risch N , MerikangasK. The future of genetic studies of complex human diseases. Science273(5281), 1516–1517 (1996).
   PubMed Web of Science ®Google Scholar
• Levy S , SuttonG, NgPCet al. The diploid genome sequence of an individual human. PLoS Biol.5(10), e254 (2007).
   PubMed Web of Science ®Google Scholar
• Abecasis GR , AutonA, BrooksLDet al. An integrated map of genetic variation from 1,092 human genomes. Nature491(7422), 56–65 (2012).
   PubMed Web of Science ®Google Scholar
• Kruglyak L , NickersonDA. Variation is the spice of life. Nat. Genet.27(3), 234–236 (2001).
   PubMed Web of Science ®Google Scholar
• Fitzgerald LM , McdonnellSK, CarlsonEEet al. Genome-wide linkage analyses of hereditary prostate cancer families with colon cancer provide further evidence for a susceptibility locus on 15q11-q14. Eur. J. Hum. Genet.18(10), 1141–1147 (2010).
   PubMed Web of Science ®Google Scholar
• Freedman ML , MonteiroAN, GaytherSAet al. Principles for the post-GWAS functional characterization of cancer risk loci. Nat. Genet.43(6), 513–518 (2011).
   PubMed Web of Science ®Google Scholar
• Hazelett DJ , RhieSK, GaddisMet al. Comprehensive functional annotation of 77 prostate cancer risk loci. PLoS Genet.10(1), e1004102 (2014).
   PubMed Web of Science ®Google Scholar
• Bonnen PE , WangPJ, KimmelM, ChakrabortyR, NelsonDL. Haplotype and linkage disequilibrium architecture for human cancer-associated genes. Genome Res.12(12), 1846–1853 (2002).
   PubMed Web of Science ®Google Scholar
• Eeles RA , Kote-JaraiZ, GilesGGet al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat. Genet.40(3), 316–321 (2008).
   PubMed Web of Science ®Google Scholar
• Hoffmann TJ , ZhanY, KvaleMNet al. Design and coverage of high throughput genotyping arrays optimized for individuals of East Asian, African American, and Latino race/ethnicity using imputation and a novel hybrid SNP selection algorithm. Genomics98(6), 422–430 (2011).
   PubMed Web of Science ®Google Scholar
• A Catalog of Published Genone Wide Asssociation Studies. www.genome.gov/26525384.
   Google Scholar
• Xu J , MoZ, YeDet al. Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4. Nat. Genet.44(11), 1231–1235 (2012).
   PubMed Web of Science ®Google Scholar
• Takata R , AkamatsuS, KuboMet al. Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat. Genet.42(9), 751–754 (2010).
   PubMed Web of Science ®Google Scholar
• Sun J , ZhengSL, WiklundFet al. Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res.69(1), 10–15 (2009).
   PubMed Web of Science ®Google Scholar
• Haiman CA , ChenGK, BlotWJet al. Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat. Genet.43(6), 570–573 (2011).
   PubMed Web of Science ®Google Scholar
• Gudmundsson J , SulemP, GudbjartssonDFet al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat. Genet.41(10), 1122–1126 (2009).
   PubMed Web of Science ®Google Scholar
• Berndt SI , SampsonJ, YeagerMet al. Large-scale fine mapping of the HNF1B locus and prostate cancer risk. Hum. Mol. Genet.20(16), 3322–3329 (2011).
   PubMed Web of Science ®Google Scholar
• Akamatsu S , TakataR, HaimanCAet al. Common variants at 11q12, 10.26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese. Nat. Genet.44(4), 426–429, s421 (2012).
   PubMed Web of Science ®Google Scholar
• Yeager M , OrrN, HayesRBet al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat. Genet.39(5), 645–649 (2007).
   PubMed Web of Science ®Google Scholar
• Thomas G , JacobsKB, YeagerMet al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat. Genet.40(3), 310–315 (2008).
   PubMed Web of Science ®Google Scholar
• Sun J , ZhengSL, WiklundFet al. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat. Genet.40(10), 1153–1155 (2008).
   PubMed Web of Science ®Google Scholar
• Schumacher FR , BerndtSI, SiddiqAet al. Genome-wide association study identifies new prostate cancer susceptibility loci. Hum. Mol. Genet.20(19), 3867–3875 (2011).
   PubMed Web of Science ®Google Scholar
• Gudmundsson J , SulemP, SteinthorsdottirVet al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat. Genet.39(8), 977–983 (2007).
   PubMed Web of Science ®Google Scholar
• Gudmundsson J , SulemP, ManolescuAet al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat. Genet.39(5), 631–637 (2007).
   PubMed Web of Science ®Google Scholar
• Duggan D , ZhengSL, KnowltonMet al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J. Natl Cancer Inst.99(24), 1836–1844 (2007).
   PubMedGoogle Scholar
• Amundadottir LT , SulemP, GudmundssonJet al. A common variant associated with prostate cancer in European and African populations. Nat. Genet.38(6), 652–658 (2006).
   PubMed Web of Science ®Google Scholar
• Kote-Jarai Z , SaundersEJ, LeongamornlertDAet al. Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum. Mol. Genet.22(12), 2520–2528 (2013).
   PubMed Web of Science ®Google Scholar
• Kote-Jarai Z , OlamaAA, GilesGGet al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat. Genet.43(8), 785–791 (2011).
   PubMed Web of Science ®Google Scholar
• Gudmundsson J , SulemP, RafnarTet al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat. Genet.40(3), 281–283 (2008).
   PubMed Web of Science ®Google Scholar
• Eeles RA , OlamaAA, BenllochSet al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat. Genet.45(4), 385–391, 391e381–382 (2013).
   PubMed Web of Science ®Google Scholar
• Al Olama AA , Kote-JaraiZ, BerndtSIet al. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat. Genet.46(10), 1103–1109 (2014).
   PubMed Web of Science ®Google Scholar
• Hsu FC , SunJ, WiklundFet al. A novel prostate cancer susceptibility locus at 19q13. Cancer Res.69(7), 2720–2723 (2009).
   PubMed Web of Science ®Google Scholar
• Amin Al Olama A , Kote-JaraiZ, SchumacherFRet al. A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum. Mol. Genet.22(2), 408–415 (2013).
   PubMed Web of Science ®Google Scholar
• Al Olama AA , Kote-JaraiZ, GilesGGet al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat. Genet.41(10), 1058–1060 (2009).
   PubMed Web of Science ®Google Scholar
• Ahmadiyeh N , PomerantzMM, GrisanzioCet al. 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc. Natl Acad. Sci. USA107(21), 9742–9746 (2010).
   PubMed Web of Science ®Google Scholar
• Eeles RA , Kote-JaraiZ, Al OlamaAAet al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat. Genet.41(10), 1116–1121 (2009).
   PubMed Web of Science ®Google Scholar
• Kote-Jarai Z , LeongamornlertD, TymrakiewiczMet al. Mutation analysis of the MSMB gene in familial prostate cancer. Br. J. Cancer102(2), 414–418 (2010).
   PubMed Web of Science ®Google Scholar
• Garde SV , BasrurVS, LiLet al. Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis. Prostate38(2), 118–125 (1999).
   PubMed Web of Science ®Google Scholar
• Bjartell A . PSA and prostate cancer screening: the challenge of the new millennium. Eur. Urol.52(5), 1284–1286 (2007).
   PubMed Web of Science ®Google Scholar
• Reeves JR , DuludeH, PanchalC, DaigneaultL, RamnaniDM. Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy. Clin. Cancer. Res.12(20 Pt 1), 6018–6022 (2006).
   PubMed Web of Science ®Google Scholar
• Whitaker HC , Kote-JaraiZ, Ross-AdamsHet al. The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PLoS ONE5(10), e13363 (2010).
   PubMed Web of Science ®Google Scholar
• Cramer SD , ChangBL, RaoAet al. Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. J. Natl Cancer Inst.95(14), 1044–1053 (2003).
   PubMed Web of Science ®Google Scholar
• Kote-Jarai Z , Amin Al OlamaA, LeongamornlertDet al. Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. Hum. Genet.129(6), 687–694 (2011).
   PubMed Web of Science ®Google Scholar
• Vickers AJ , CroninAM, AusGet al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. BMC Med.6, 19 (2008).
   PubMed Web of Science ®Google Scholar
• Manolio TA , CollinsFS, CoxNJet al. Finding the missing heritability of complex diseases. Nature461(7265), 747–753 (2009).
   PubMed Web of Science ®Google Scholar
• Thompson D , EastonD. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am. J. Hum. Genet.68(2), 410–419 (2001).
   PubMed Web of Science ®Google Scholar
• Kote-Jarai Z , LeongamornlertD, SaundersEet al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br. J. Cancer105(8), 1230–1234 (2011).
   PubMed Web of Science ®Google Scholar
• Leongamornlert D , MahmudN, TymrakiewiczMet al. Germline BRCA1 mutations increase prostate cancer risk. Br. J. Cancer106(10), 1697–1701 (2012).
   PubMed Web of Science ®Google Scholar
• Robinson D , Van AllenEM, WuYMet al. Integrative clinical genomics of advanced prostate cancer. Cell161(5), 1215–1228 (2015).
   PubMed Web of Science ®Google Scholar
• Narod SA , NeuhausenS, VichodezGet al. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br. J. Cancer99(2), 371–374 (2008).
   PubMed Web of Science ®Google Scholar
• Tryggvadottir L , VidarsdottirL, ThorgeirssonTet al. Prostate cancer progression and survival in BRCA2 mutation carriers. J. Natl Cancer Inst.99(12), 929–935 (2007).
   PubMedGoogle Scholar
• Castro E , GohC, OlmosDet al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J. Clin. Oncol.31(14), 1748–1757 (2013).
   PubMed Web of Science ®Google Scholar
• Castro E , GohC, LeongamornlertDet al. Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. Eur. Urol.68(2), 186–193 (2015).
   PubMed Web of Science ®Google Scholar
• Economides KD , CapecchiMR. Hoxb13 is required for normal differentiation and secretory function of the ventral prostate. Development130(10), 2061–2069 (2003).
   PubMed Web of Science ®Google Scholar
• Kim YR , OhKJ, ParkRYet al. HOXB13 promotes androgen independent growth of LNCaP prostate cancer cells by the activation of E2F signaling. Mol. Cancer9, 124 (2010).
   PubMed Web of Science ®Google Scholar
• Xu J , LangeEM, LuLet al. HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum. Genet.132(1), 5–14 (2013).
   PubMed Web of Science ®Google Scholar
• Eeles R , GohC, CastroEet al. The genetic epidemiology of prostate cancer and its clinical implications. Nat. Rev. Urol.11(1), 18–31 (2013).
   PubMed Web of Science ®Google Scholar
• Bloss CS , DarstBF, TopolEJ, SchorkNJ. Direct-to-consumer personalized genomic testing. Hum. Mol. Genet.20(R2), R132–R141 (2011).
   PubMedGoogle Scholar
• Macinnis RJ , AntoniouAC, EelesRAet al. A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact. Genet. Epidemiol.35(6), 549–556 (2011).
   PubMed Web of Science ®Google Scholar
• Chou R , CroswellJM, DanaTet al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann. Intern. Med.155(11), 762–771 (2011).
   PubMed Web of Science ®Google Scholar
• Burford Dc KM , AustokerJ. Prostate cancer risk management programme: information for primary care; PSA testing in asymptomatic men (2009). www.gov.scot/resource/doc/1094/0088915.pdf.
   Google Scholar
• Schroder FH , HugossonJ, RoobolMJet al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med.360(13), 1320–1328 (2009).
   PubMed Web of Science ®Google Scholar
• Hugosson J , CarlssonS, AusGet al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol.11(8), 725–732 (2010).
   PubMed Web of Science ®Google Scholar
• Andriole GL , CrawfordED, GrubbRLet al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J. Natl Cancer Inst.104(2), 125–132 (2012).
   PubMedGoogle Scholar
• Pisansky TM . External-beam radiotherapy for localized prostate cancer. N. Engl. J. Med.355(15), 1583–1591 (2006).
   PubMed Web of Science ®Google Scholar
• Barnett GC , WestCM, DunningAMet al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat. Rev. Cancer9(2), 134–142 (2009).
   PubMed Web of Science ®Google Scholar
• Bentzen SM . Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat. Rev. Cancer6(9), 702–713 (2006).
   PubMed Web of Science ®Google Scholar
• Kerns SL , OstrerH, StockRet al. Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys.78(5), 1292–1300 (2010).
   PubMed Web of Science ®Google Scholar
• Kerns SL , StockR, StoneNet al. A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of erectile dysfunction following radiation therapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys.85(1), e21–e28 (2013).
   PubMed Web of Science ®Google Scholar
• Kerns SL , StoneNN, StockRG, RathL, OstrerH, RosensteinBS. A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of urinary symptoms after radiotherapy for prostate cancer. J. Urol.190(1), 102–108 (2013).
   PubMed Web of Science ®Google Scholar
• West C , RosensteinBS, AlsnerJet al. Establishment of a radiogenomics consortium. Int. J. Radiat. Oncol. Biol. Phys.76(5), 1295–1296 (2010).
   PubMed Web of Science ®Google Scholar
• Huang SP , TingWC, ChenLMet al. Association analysis of Wnt pathway genes on prostate-specific antigen recurrence after radical prostatectomy. Ann. Surg. Oncol.17(1), 312–322 (2010).
   PubMed Web of Science ®Google Scholar
• Strom SS , GuY, ZhangHet al. Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients. Prostate60(4), 343–351 (2004).
   PubMed Web of Science ®Google Scholar
• Kantoff PW , HiganoCS, ShoreNDet al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med.363(5), 411–422 (2010).
   PubMed Web of Science ®Google Scholar
• Audet-Walsh E , BellemareJ, NadeauGet al. SRD5A polymorphisms and biochemical failure after radical prostatectomy. Eur. Urol.60(6), 1226–1234 (2011).
   PubMed Web of Science ®Google Scholar
• Larson BT , Magi-GalluzziC, CaseyG, PlummerSJ, SilvermanR, KleinEA. Pathological aggressiveness of prostatic carcinomas related to RNASEL R462Q allelic variants. J. Urol.179(4), 1344–1348 (2008).
   PubMed Web of Science ®Google Scholar
• Dluzniewski PJ , WangMH, ZhengSLet al. Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence. Cancer Epidemiol. Biomarkers Prev.21(10), 1774–1782 (2012).
   PubMed Web of Science ®Google Scholar
• Morote J , Del AmoJ, BorqueAet al. Improved prediction of biochemical recurrence after radical prostatectomy by genetic polymorphisms. J. Urol.184(2), 506–511 (2010).
   PubMed Web of Science ®Google Scholar
• Watanabe M , UshijimaT, ShiraishiTet al. Genetic alterations of androgen receptor gene in Japanese human prostate cancer. Jpn. J. Clin. Oncol.27(6), 389–393 (1997).
   PubMed Web of Science ®Google Scholar
• Hirata H , HinodaY, KikunoNet al. Bcl2 -938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy. J. Urol.181(4), 1907–1912 (2009).
   PubMed Web of Science ®Google Scholar
• Whitman EJ , PomerantzM, ChenYet al. Prostate cancer risk allele specific for African descent associates with pathologic stage at prostatectomy. Cancer Epidemiol. Biomarkers Prev.19(1), 1–8 (2010).
   PubMed Web of Science ®Google Scholar
• Kader AK , SunJ, IsaacsSDet al. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate69(11), 1195–1205 (2009).
   PubMed Web of Science ®Google Scholar
• Smith MR . Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr. Opin. Endocrinol. Diabetes Obes.14(3), 247–254 (2007).
   PubMedGoogle Scholar
• Lindstrom S , AdamiHO, BalterKAet al. Inherited variation in hormone-regulating genes and prostate cancer survival. Clin. Cancer. Res.13(17), 5156–5161 (2007).
   PubMed Web of Science ®Google Scholar
• Maki HE , WalteringKK, WallenMJet al. Screening of genetic and expression alterations of SRC1 gene in prostate cancer. Prostate66(13), 1391–1398 (2006).
   PubMed Web of Science ®Google Scholar
• Yang M , XieW, MostaghelEet al. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J. Clin. Oncol.29(18), 2565–2573 (2011).
   PubMed Web of Science ®Google Scholar
• Huang CN , HuangSP, PaoJBet al. Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy. Ann. Oncol.23(3), 707–713 (2012).
   PubMed Web of Science ®Google Scholar
• Sun T , LeeGS, WernerLet al. Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy. Cancer Epidemiol. Biomarkers Prev.19(7), 1871–1878 (2010).
   PubMed Web of Science ®Google Scholar
• Tannock IF , De WitR, BerryWRet al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med.351(15), 1502–1512 (2004).
   PubMed Web of Science ®Google Scholar
• Sissung TM , DanesiR, PriceDKet al. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol. Cancer Ther.7(1), 19–26 (2008).
   PubMed Web of Science ®Google Scholar
• Narita S , TsuchiyaN, YuasaTet al. Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer. Int. J. Clin. Oncol.17(3), 204–211 (2012).
   PubMed Web of Science ®Google Scholar
• Chi KN , HotteSJ, YuEYet al. Randomized phase II study of docetaxel and prednisone with or without OGX–011 in patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol.28(27), 4247–4254 (2010).
   PubMed Web of Science ®Google Scholar
• Chan JM , GiovannucciEL. Dairy products, calcium, and vitamin D and risk of prostate cancer. Epidemiol. Rev.23(1), 87–92 (2001).
   PubMed Web of Science ®Google Scholar
• Kolonel LN . Fat, meat, and prostate cancer. Epidemiol. Rev.23(1), 72–81 (2001).
   PubMed Web of Science ®Google Scholar
• Giovannucci E . Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J. Natl Cancer Inst.91(4), 317–331 (1999).
   PubMedGoogle Scholar
• Thompson IM , GoodmanPJ, TangenCMet al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med.349(3), 215–224 (2003).
   PubMed Web of Science ®Google Scholar
• Madersbacher S . Words of wisdom. Re: Effect of dutasteride on the risk of prostate cancer. Andriole GL, Bostwick DG, Brawley OW et al. REDUCE Study Group. N Engl J Med 2010;362:1192–202. Eur. Urol.58(2), 312 (2010).
   PubMedGoogle Scholar
• Walsh PC . Chemoprevention of prostate cancer. N. Engl. J. Med.362(13), 1237–1238 (2010).
   PubMed Web of Science ®Google Scholar
• Castro E , GohC, LeongamornlertDet al. Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. Eur. Urol.68(2), 186–193 (2014).
   PubMed Web of Science ®Google Scholar
• ELLIPSE (Elucidating Loci Involved in Prostate Cancer Susceptibility). http://maps.cancer.gov/overview/DCCPSGrants/abstract.jsp?applId=8540134&term=CA148537.
   Google Scholar
• National Cancer Institute . Breast and Prostate Cancer Consortium (Online) (BPC3). http://epi.grants.cancer.gov/BPC3/.
   Google Scholar
• Karolinska Institute . Cancer in the Prostate (Caps). http://ki.se/en/meb/cancer-of-the-prostate-in-sweden-caps.
   Google Scholar
• National Institue fo Health . Cancer Genetic Markers of Susceptibility (CGEMS). http://dceg.cancer.gov/research/how-we-study/genomic-studies/cgems-summary.
   Google Scholar
• Natioanl Institute of Health . Elucidating Loci Involved In Prostate Cancer Susceptibility (ELLIPSE). http://epi.grants.cancer.gov/gameon/.
   Google Scholar
• International Consortium for Prostate Cancer Genetics (ICPCG) . www.icpcg.org/.
   Google Scholar
• The Identification of Men with a Genetic Predisposition to Prostate Cancer: Targeted Screening in BRCA1/BRCA2 mutation carriers and controls. www.impact-study.co.uk/.
   Google Scholar
• NIH . Men of African Descent and Carcinoma of the Prostate Consortium. http://epi.grants.cancer.gov/madcap/.
   Google Scholar
• Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL). http://practical.ccge.medschl.cam.ac.uk/.
   Google Scholar
• Germline Genetic Profiling: Correlation with Targeted Prostate Cancer Screening and Treatment. www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-find-out-looking-gene-changes-would-be-useful-in-screening-for-prostate-cancer-profile-pilot.
   Google Scholar